Q3 EPS Estimates for Apogee Therapeutics Cut by Wedbush

Apogee Therapeutics, Inc. (NASDAQ:APGE) – Equities research analysts at Wedbush decreased their Q3 2025 earnings per share estimates for shares of Apogee Therapeutics in a note issued to investors on Monday, December 2nd. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.97) per share for the quarter, down from their prior estimate of ($0.95). Wedbush currently has a “Outperform” rating and a $90.00 target price on the stock. The consensus estimate for Apogee Therapeutics’ current full-year earnings is ($2.81) per share. Wedbush also issued estimates for Apogee Therapeutics’ FY2025 earnings at ($3.93) EPS, FY2026 earnings at ($4.06) EPS, FY2027 earnings at ($4.46) EPS and FY2028 earnings at ($5.93) EPS.

Several other brokerages have also commented on APGE. Guggenheim restated a “buy” rating and set a $110.00 target price (up from $95.00) on shares of Apogee Therapeutics in a research report on Tuesday. Canaccord Genuity Group initiated coverage on shares of Apogee Therapeutics in a research report on Monday, November 25th. They set a “buy” rating and a $89.00 target price on the stock. Finally, Canaccord Genuity Group began coverage on shares of Apogee Therapeutics in a research report on Monday, November 25th. They set a “buy” rating and a $89.00 price target for the company. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Apogee Therapeutics currently has an average rating of “Buy” and an average target price of $83.88.

Apogee Therapeutics Price Performance

Shares of APGE stock opened at $46.26 on Wednesday. The business’s fifty day moving average price is $52.90 and its 200 day moving average price is $48.30. The firm has a market capitalization of $2.08 billion, a PE ratio of -19.12 and a beta of 2.30. Apogee Therapeutics has a 1-year low of $18.84 and a 1-year high of $72.29.

Insider Activity at Apogee Therapeutics

In other Apogee Therapeutics news, CEO Michael Thomas Henderson sold 40,000 shares of Apogee Therapeutics stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $56.23, for a total value of $2,249,200.00. Following the completion of the sale, the chief executive officer now owns 1,354,487 shares in the company, valued at $76,162,804.01. The trade was a 2.87 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Carl Dambkowski sold 6,665 shares of the firm’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $59.12, for a total transaction of $394,034.80. Following the completion of the sale, the insider now directly owns 267,463 shares in the company, valued at $15,812,412.56. This represents a 2.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 68,330 shares of company stock valued at $3,906,508 over the last quarter. Insiders own 36.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in APGE. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Apogee Therapeutics during the third quarter worth about $71,000. Mirae Asset Global Investments Co. Ltd. increased its position in Apogee Therapeutics by 21.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,628 shares of the company’s stock worth $94,000 after purchasing an additional 285 shares in the last quarter. Allspring Global Investments Holdings LLC purchased a new position in Apogee Therapeutics in the second quarter valued at approximately $143,000. Wexford Capital LP purchased a new position in Apogee Therapeutics in the third quarter valued at approximately $230,000. Finally, Intech Investment Management LLC acquired a new position in Apogee Therapeutics during the third quarter valued at approximately $300,000. Institutional investors and hedge funds own 79.04% of the company’s stock.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.